Back to Search Start Over

Hollow Mesoporous CeO2-Based Nanoenzymes Fabrication for Effective Synergistic Eradication of Malignant Breast Cancer via Photothermal–Chemodynamic Therapy

Authors :
Huaxin Tan
Yongzhen Li
Jiaying Ma
Peiyuan Wang
Qiaoling Chen
Lidan Hu
Source :
Pharmaceutics, Vol 14, Iss 8, p 1717 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

CeO2-based nanoenzymes present a very promising paradigm in cancerous therapy, as H2O2 can be effectively decomposed under the electron transmit between Ce3+ and Ce4+. However, the limitations of endogenous H2O2 and intracellular low Fenton-like reaction rate lead to single unsatisfied chemodynamic therapy (CDT) efficacy. Other therapeutic modalities combined with chemodynamic therapy are generally used to enhance the tumor eradiation efficacy. Here, we have synthesized a novel hollow pH-sensitive CeO2 nanoenzyme after a cavity is loaded with indocyanine green (ICG), as well as with surface modification of tumor targeting peptides, Arg-Gly-Asp (denoted as HCeO2@ICG-RGD), to successfully target tumor cells via αvβ3 recognition. Importantly, in comparison with single chemodynamic therapy, a large amount of reactive oxygen species in cytoplasm were induced by enhanced chemodynamic therapy with photothermal therapy (PTT). Furthermore, tumor cells were efficiently killed by a combination of photothermal and chemodynamic therapy, revealing that synergistic therapy was successfully constructed. This is mainly due to the precise delivery of ICG and release after HCeO2 decomposition in cytoplasm, in which effective hyperthermia generation was found under 808 nm laser irradiation. Meanwhile, our HCeO2@ICG-RGD can act as a fluorescent imaging contrast agent for an evaluation of tumor tissue targeting capability in vivo. Finally, we found that almost all tumors in HCeO2@ICG-RGD+laser groups were completely eradicated in breast cancer bearing mice, further proving the effective synergistic effect in vivo. Therefore, our novel CeO2-based PTT agents provide a proof-of-concept argumentation of tumor-precise multi-mode therapies in preclinical applications.

Details

Language :
English
ISSN :
14081717 and 19994923
Volume :
14
Issue :
8
Database :
Directory of Open Access Journals
Journal :
Pharmaceutics
Publication Type :
Academic Journal
Accession number :
edsdoj.9a0c90cbb064412ad5370805a95a085
Document Type :
article
Full Text :
https://doi.org/10.3390/pharmaceutics14081717